Montalbo, RuthLozano, Juan JIzquierdo, LauraIngelmo-Torres, MercedesBaÑos, CarmenPalou, JoanVan der Heijden, Antoine GMedina, RafaelSchmidbauer, JoergPrat, AleixRibal, Maria JAlcaraz, AntonioMengual, Lourdes2023-01-252023-01-252019-02-07http://hdl.handle.net/10668/13574This study aimed to improve our previous urine gene expression classifiers focusing on the detection of non-high-risk non-muscle-invasive bladder cancer (NMIBC), and develop a new classifier able to decrease the frequency of cystoscopies during bladder cancer (BC) patients' surveillance. A total of 597 urines from BC patients, controls and patients in follow-up for BC (PFBC) were included. The study has 3 phases. In the urinary biomarker discovery phase, 84 urines from BC and control patients were retrospectively included and analyzed by Ribonucleic Acid (RNA) sequencing. In the classifier development phase, a total of 132 selected genes from previous phase were evaluated by nCounter in 214 prospectively collected urines from PFBC (98 with tumor). A diagnostic classifier was generated by logistic regression. Finally, in the classifier validation phase, a multicentric and international cohort of 248 urines (134 BC and 114 nonrecurrent PFBC) was used to validate classifier performance. A total of 521 genes were found differentially expressed between non-high-risk NMIBC samples and all other groups (PenAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AgedAged, 80 and overBiomarkersCystoscopyFemaleGene Expression ProfilingHumansMaleMiddle AgedReproducibility of ResultsUrinary Bladder NeoplasmsUrineresearch article30771285open access10.1016/j.trsl.2019.02.0031878-1810http://diposit.ub.edu/dspace/bitstream/2445/130889/1/686534.pdf